Advice

in the absence of a submission from the holder of the marketing authorisation:

eribulin (HalavenĀ®) is not recommended for use within NHSScotland.

Indication under review: Treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Download detailed advice354KB (PDF)

Download

Medicine details

Medicine name:
eribulin (Halaven)
SMC ID:
SMC2231
Indication:

Treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease.

Pharmaceutical company
Eisai Ltd
BNF chapter
Submission type
Non submission
Status
Not recommended
Date advice published:
09 September 2019